Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Payables: 2014-2025

Historic Payables for vTv Therapeutics (VTVT) over the last 11 years, with Sep 2025 value amounting to $10.1 million.

  • vTv Therapeutics' Payables rose 62.72% to $10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.6 million, marking a year-over-year decrease of 23.67%. This contributed to the annual value of $5.0 million for FY2024, which is 51.82% down from last year.
  • According to the latest figures from Q3 2025, vTv Therapeutics' Payables is $10.1 million, which was up 94.23% from $5.2 million recorded in Q2 2025.
  • vTv Therapeutics' 5-year Payables high stood at $12.5 million for Q1 2022, and its period low was $4.2 million during Q1 2025.
  • For the 3-year period, vTv Therapeutics' Payables averaged around $7.7 million, with its median value being $8.4 million (2023).
  • Per our database at Business Quant, vTv Therapeutics' Payables crashed by 57.93% in 2021 and then spiked by 151.24% in 2022.
  • Over the past 5 years, vTv Therapeutics' Payables (Quarterly) stood at $8.3 million in 2021, then dropped by 8.96% to $7.5 million in 2022, then skyrocketed by 38.42% to $10.4 million in 2023, then slumped by 51.82% to $5.0 million in 2024, then surged by 62.72% to $10.1 million in 2025.
  • Its Payables stands at $10.1 million for Q3 2025, versus $5.2 million for Q2 2025 and $4.2 million for Q1 2025.